CELLDEX THERAPEUTICS INC shares fell 15% on Tuesday afternoon after two cases of anaphylaxis clouded positive late-stage trial results for its skin drug. The drop came despite the experimental treatment meeting its primary endpoints in chronic spontaneous urticaria. Investors focused heavily on the safety signals as the company cleared a hurdle toward a U.S. regulatory filing.

Trial Efficacy Versus Safety Signals